Meyer Jessica Sayre, Riese Jeffrey, Biondi Eric
The Warren Alpert Medical School of Brown University, Rhode Island Hospital/Hasbro Children's Hospital, Department of Pediatrics, Providence, Rhode Island; and.
Hosp Pediatr. 2014 May;4(3):172-80. doi: 10.1542/hpeds.2013-0088.
A short course of systemic corticosteroids is an important therapy in the treatment of pediatric asthma exacerbations. Although a 5-day course of oral prednisone or prednisolone has become the most commonly used regimen, dexamethasone has also been used for a shorter duration (1-2 days) with potential for improvement in compliance and palatability. We reviewed the literature to determine if there is sufficient evidence that dexamethasone can be used as an effective alternative in the treatment of pediatric asthma exacerbations in the inpatient setting.
A Medline search was conducted on the use of dexamethasone in the treatment of asthma exacerbations in children. The studies selected were clinical trials comparing the efficacy of dexamethasone with prednisone. Meta-analysis was performed examining physician revisitation rates and symptomatic return to baseline.
Six completed pediatric clinical trials met the inclusion criteria. All of the pediatric trials found that prednisone is not superior to dexamethasone in treating mild to moderate asthma exacerbations. Meta-analysis demonstrated homogeneity between the dexamethasone and prednisone groups when examining symptomatic return to baseline and unplanned physician revisits after the initial emergency department encounter. Some studies found potential additional benefits of dexamethasone, including improved compliance and less vomiting.
The current literature suggests that dexamethasone can be used as an effective alternative to prednisone in the treatment of mild to moderate acute asthma exacerbations in children, with the added benefits of improved compliance, palatability, and cost. However, more research is needed to examine the role of dexamethasone in hospitalized children.
短期全身性使用糖皮质激素是治疗小儿哮喘急性发作的重要疗法。尽管5天疗程的口服泼尼松或泼尼松龙已成为最常用的治疗方案,但地塞米松也已被用于更短疗程(1 - 2天),这有可能提高依从性和改善口感。我们回顾了相关文献,以确定是否有充分证据表明地塞米松可作为住院小儿哮喘急性发作治疗的有效替代药物。
对使用地塞米松治疗儿童哮喘急性发作的情况进行了Medline检索。所选择的研究为比较地塞米松与泼尼松疗效的临床试验。进行了荟萃分析,以检查医生复诊率和症状恢复至基线的情况。
六项已完成的儿科临床试验符合纳入标准。所有儿科试验均发现,在治疗轻度至中度哮喘急性发作方面,泼尼松并不优于地塞米松。荟萃分析表明,在地塞米松组和泼尼松组之间,在检查症状恢复至基线以及初次急诊科就诊后非计划的医生复诊情况时具有同质性。一些研究发现地塞米松可能还有其他益处,包括提高依从性和减少呕吐。
当前文献表明,地塞米松可作为泼尼松的有效替代药物用于治疗儿童轻度至中度急性哮喘发作,具有提高依从性、改善口感和降低成本等额外益处。然而,需要更多研究来考察地塞米松在住院儿童中的作用。